Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Mus musculus

ABSTRACT: Bazedoxifene and conjugated estrogen combination improves gut-liver axis health [mouse liver]

PROVIDER: PRJNA359187 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR5133590.fastq.gz	Fastqsanger.gz
	SRR5133581.fastq.gz	Fastqsanger.gz
	SRR5133591.fastq.gz	Fastqsanger.gz
	SRR5133582.fastq.gz	Fastqsanger.gz
	SRR5133592.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 15

Similar Datasets

Bazedoxifene and conjugated estrogen combination improves gut-liver axis health

Project description:Bazedoxifene and conjugated estrogen combination improves gut-liver axis health

| PRJNA360113 | ENA

mouse gut metagenome

Project description:Bazedoxifene and conjugated estrogen combination improves gut-liver axis health [microbiota]

| PRJNA360111 | ENA

Bazedoxifene and conjugated estrogen combination improves gut-liver axis health [mouse liver]

Project description:Bazedoxifene and conjugated estrogens (CE+BZA) combination has been shown to prevent visceral adiposity and weight gain after menopause. However, its interaction with the microbiota has yet to be examined. In the present study, we use several –omics technologies to characterize the effects of various estrogens on the health of gut-liver axis. As reported in previous studies, CE+BZA combination is very effective at preventing ovariectomy-induced weight gain in mice fed a high-fat diet. Additionally, CE+BZA induces unique liver transcriptomic and blood metabolite profiles compared to estradiol, conjugated estrogens alone, and bazedoxifene alone. Several pathways and metabolites influenced are associated with lower rates of inflammation and overall benefits to gut and liver health. Finally, microbiome analysis shows that several bacterial species that potentially metabolize estrogens and affect their half-life in the body were significantly changed in CE+BZA treated mice. Our findings indicate a possible link between certain estrogens and gut microbiome and suggest a metabolic benefit of estrogens through manipulation of the gut-liver axis.

2018-02-13 | GSE92968 | GEO

Bazedoxifene and conjugated estrogen combination improves gut-liver axis health [microbiota]

2019-12-28 | GSE93096 | GEO

Physiomimetic model of the human Gut-Liver axis for studies of inflammatory diseases

Project description:Association between the microbiome, IBD and liver diseases are known, yet cause and effect remain elusive. By connecting human microphysiological systems of the gut, liver and circulating Treg/Th17 cells, we modeled progression of ulcerative colitis (UC) ex vivo. We show that microbiome-derived short-chain fatty acids (SCFA) may either improve or worsen disease severity, depending on the activation state of CD4 T cells. Employing a multiomic approach, we found SCFA reduced innate activation of the UC gut and increased hepatic metabolism. However, during acute T cell-mediated inflammation, SCFA exacerbate CD4 T cell effector function leading to gut barrier disruption and liver damage. These paradoxical findings underscore the emerging utility of human physiomimetic technology in combination with systems immunology to study causality and temporal facets of gut-liver axis related diseases where animal models might leave ambiguity.

2021-06-03 | GSE135428 | GEO

Cell atlas of mouse colon tissues of liver cirrhosis mouse

Project description:Liver disease alters the gut microenvironment by liver-gut axis. To investigate the composition and transcriptome changes of various intestinal cell populations in liver cirrhosis, we delineated a single-cell atlas of the colon from mice treated CCl4 for 6 weeks.

2022-11-22 | GSE218371 | GEO

Project description:Polysaccharide Gut Liver Axis

| PRJNA936077 | ENA

Gut-derived indole propionic acid alleviates liver fibrosis by modulating pro-fibrogenic macrophage phenotype and biological function

Project description:Recently, gut metabolites have been recognized to play significant roles in liver diseases via the gut-liver axis. In this study, we investigate the regulatory effects of the tryptophan metabolite, indole-3-propionic acid (IPA), on immune cells during liver fibrogenesis using single-cell RNA sequencing (scRNA-seq).

2024-09-20 | GSE277148 | GEO

Prominent role of gut dysbiosis in the pathogenesis of cystic fibrosis-related liver disease in mice

Project description:Cystic fibrosis-related liver disease (CFLD) is a chronic cholangiopathy that increases morbidity and mortality in patients with CF. Current treatments are unsatisfactory, and incomplete understanding of CFLD pathogenesis hampers therapeutic development. We have previously shown that mouse CF cholangiocytes respond with excessive inflammation to LPS. Thus, we investigated the role of the gut-liver axis in the pathogenesis of CFLD.

2024-09-13 | GSE238000 | GEO

Integrated Gut/Liver-on-a-Chip platform as in vitro human model of non-alcoholic fatty liver disease

Project description:Non-alcoholic fatty liver disease (NAFLD) influence one of third population around the world. Until now, no effective treatments have been established due to the improper in vitro assays and experimental animal models. By co-culturing human gut and liver cell lines (CaCO2 and HepG2 cells, respectively) interconnected via the microfluidic closed medium circulation loop, we created a gut-liver-on-a-chip (iGLC) platform as an in vitro human model of the gut-liver axis (GLA) in initiation and progression of NAFLD.

2023-03-01 | GSE152091 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data